PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 3340人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254912, encodeId=e68f12549120d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：非小细胞肺癌的PD-L1检测，谁主沉浮？, objectType=article, longId=94843, objectId=1c09948438c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c09948438c, replyNumber=0, likeNumber=31, createdTime=2017-04-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c09948438c, moduleTitle=JAMA Oncol：非小细胞肺癌的PD-L1检测，谁主沉浮？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c09948438c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254911, encodeId=6e8612549116e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Commun：溶瘤病毒可协同PD-L1抗体抗癌, objectType=article, longId=94024, objectId=d18e9402496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d18e9402496, replyNumber=0, likeNumber=39, createdTime=2017-04-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d18e9402496, moduleTitle=Nat Commun：溶瘤病毒可协同PD-L1抗体抗癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d18e9402496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254910, encodeId=ee4d1254910c7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, objectType=article, longId=93675, objectId=64f6936e500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64f6936e500, replyNumber=0, likeNumber=38, createdTime=2017-03-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64f6936e500, moduleTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64f6936e500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254909, encodeId=e8c31254909d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=47个药物拼“钱途”！PD-1/PD-L1抗体太“火”了……, objectType=article, longId=92500, objectId=955292500e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=955292500e0, replyNumber=0, likeNumber=35, createdTime=2017-03-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=955292500e0, moduleTitle=47个药物拼“钱途”！PD-1/PD-L1抗体太“火”了……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=955292500e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254908, encodeId=a65f12549089f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：对于接受PD-L1的靶向治疗的病人实行骨髓移植会有增强的早期排异反应和少量的复发危险, objectType=article, longId=91411, objectId=cb6f91411e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb6f91411e4, replyNumber=0, likeNumber=35, createdTime=2017-03-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb6f91411e4, moduleTitle=Blood：对于接受PD-L1的靶向治疗的病人实行骨髓移植会有增强的早期排异反应和少量的复发危险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb6f91411e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254907, encodeId=f7f1125490ee1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Science: 保持T细胞CD28/B7信号通路的激活对于针对PD-L1的靶向治疗具有重大意义, objectType=article, longId=91389, objectId=a5ac91389a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5ac91389a2, replyNumber=0, likeNumber=42, createdTime=2017-03-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5ac91389a2, moduleTitle=Science: 保持T细胞CD28/B7信号通路的激活对于针对PD-L1的靶向治疗具有重大意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5ac91389a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254906, encodeId=78f0125490621, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=88246, objectId=abae8824611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abae8824611, replyNumber=0, likeNumber=36, createdTime=2017-02-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abae8824611, moduleTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abae8824611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254905, encodeId=9d7e12549053a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=陈列平：抗PD-1/PD-L1抗体治疗的三大原理, objectType=article, longId=86929, objectId=54688692931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54688692931, replyNumber=0, likeNumber=41, createdTime=2017-01-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54688692931, moduleTitle=陈列平：抗PD-1/PD-L1抗体治疗的三大原理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54688692931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254904, encodeId=76e9125490437, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件, objectType=article, longId=86908, objectId=4ca38690865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ca38690865, replyNumber=0, likeNumber=28, createdTime=2017-01-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ca38690865, moduleTitle=康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ca38690865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254903, encodeId=793b1254903d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=85252, objectId=aeb08525282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb08525282, replyNumber=0, likeNumber=33, createdTime=2016-12-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb08525282, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb08525282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254902, encodeId=455a12549024b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, objectType=article, longId=81794, objectId=916481e9401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916481e9401, replyNumber=0, likeNumber=12, createdTime=2016-11-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916481e9401, moduleTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=916481e9401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254901, encodeId=0c0f125490179, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, objectType=article, longId=81159, objectId=fe928115907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe928115907, replyNumber=0, likeNumber=29, createdTime=2016-10-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe928115907, moduleTitle=FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe928115907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254899, encodeId=53cd12548993e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1抗体用于二线肺癌：FDA批准，NCCN拒绝, objectType=article, longId=80714, objectId=9d7c80e14b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d7c80e14b3, replyNumber=0, likeNumber=40, createdTime=2016-10-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d7c80e14b3, moduleTitle=PD-L1抗体用于二线肺癌：FDA批准，NCCN拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d7c80e14b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254900, encodeId=76b912549009d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）, objectType=article, longId=80716, objectId=9fb980e16a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb980e16a1, replyNumber=0, likeNumber=40, createdTime=2016-10-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb980e16a1, moduleTitle=罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb980e16a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254898, encodeId=26f21254898f0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, objectType=article, longId=80506, objectId=016d805060a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=016d805060a, replyNumber=0, likeNumber=38, createdTime=2016-10-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=016d805060a, moduleTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=016d805060a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254897, encodeId=5b51125489ecc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, objectType=article, longId=79695, objectId=2555e969519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2555e969519, replyNumber=0, likeNumber=37, createdTime=2016-10-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2555e969519, moduleTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2555e969519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254896, encodeId=85ab125489621, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=32, createdTime=2016-09-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254895, encodeId=79c812548957e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, objectType=article, longId=76606, objectId=6a9fe6606af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9fe6606af, replyNumber=0, likeNumber=34, createdTime=2016-09-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9fe6606af, moduleTitle=Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9fe6606af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254894, encodeId=c3a31254894d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=雾里看花：PD-1/PD-L1抗体疗效评价的困惑, objectType=article, longId=74309, objectId=5773e430947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5773e430947, replyNumber=0, likeNumber=34, createdTime=2016-08-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5773e430947, moduleTitle=雾里看花：PD-1/PD-L1抗体疗效评价的困惑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5773e430947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254893, encodeId=f0ee125489355, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应, objectType=article, longId=73598, objectId=b0cde3598a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cde3598a5, replyNumber=0, likeNumber=29, createdTime=2016-07-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cde3598a5, moduleTitle=Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cde3598a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：非小细胞肺癌的PD-L1检测，谁主沉浮？

2017-04-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Commun：溶瘤病毒可协同PD-L1抗体抗癌

2017-04-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下

2017-03-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

47个药物拼“钱途”！PD-1/PD-L1抗体太“火”了……

2017-03-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：对于接受PD-L1的靶向治疗的病人实行骨髓移植会有增强的早期排异反应和少量的复发危险

2017-03-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Science: 保持T细胞CD28/B7信号通路的激活对于针对PD-L1的靶向治疗具有重大意义

2017-03-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2017-02-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

陈列平：抗PD-1/PD-L1抗体治疗的三大原理

2017-01-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件

2017-01-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2016-12-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）

2016-11-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA批准pembrolizumab作为高表达PD-L1转移性NSCLC的一线治疗

2016-10-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1抗体用于二线肺癌：FDA批准，NCCN拒绝

2016-10-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）

2016-10-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症

2016-10-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著

2016-10-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格

2016-09-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制

2016-09-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

雾里看花：PD-1/PD-L1抗体疗效评价的困惑

2016-08-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应

2016-07-25

科室
- - 订阅+
  - 更多科室
工具
服务